SCHEMBL423307

SCHEMBL423307

Cc1cnc(Cl)c(C)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30019862 1.00
Hydrochloric Acid SCHEMBL27746574 0.97 NOS3 (0.50)
SCHEMBL29427127 0.79
SCHEMBL30017969 0.79
SCHEMBL165105 0.79
SCHEMBL153364 0.79
SCHEMBL221321 0.75
SCHEMBL1156177 0.75
SCHEMBL22564750 0.75
SCHEMBL20544775 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 US disclosed
WO-2024138211-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. (US) 2024-06-27 WO disclosed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 US disclosed
CN-112236423-B Piperidinyl-3- (aryloxy) propanamides and propionic acid esters 武田药品工业株式会社 2024-02-06 CN disclosed
US-20230338429-A1 COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS UNIVERSITE DE MONTREAL (CA) 2023-10-26 US disclosed
US-20230303552-A1 ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS VANDERBILT UNIVERSITY 2023-09-28 US disclosed
US-20230265054-A1 PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2023-08-24 US disclosed
US-20230265054-A1 PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2023-08-24 US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
US-4665186-A 2,2,4,4-tetrasubstituted 4-formylbutyronitrile intermediates for the production of trisubstituted pyridines CIBA-GEIGY CORPORATION (US) 1987-05-12 US disclosed
US-4508905-A GASTRIC ACID SECRETION INHIBITORS AKTIEBOLAGET HASSLE (SE) 1985-04-02 US disclosed
EP-0046735-B1 PROCESS FOR THE PREPARATION OF CHLOROPYRIDINES SUBSTITUTED WITH METHYL OR TRIFLUOROMETHYL GROUPS CIBA-GEIGY AG (CH) 1984-12-12 EP disclosed
US-4469896-A Process for the production of chloropyridines substituted by methyl, trichloromethyl or trifluoromethyl groups CIBA-GEIGY CORPORATION (US) 1984-09-04 US disclosed
US-4359465-A HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES THE UPJOHN COMPANY (US) 1982-11-16 US disclosed
US-4337257-A Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion AKTIEBOLAGET HASSLE (SE) 1982-06-29 US disclosed
EP-0046735-A2 Process for the preparation of chloropyridines substituted with methyl or trifluoromethyl groups CIBA-GEIGY AG (CH) 1982-03-03 EP disclosed
EP-0005129-B1 SUBSTITUTED PYRIDYLSULFINYLBENZIMIDAZOLES HAVING GASTRIC ACID SECRETION PROPERTIES, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND INTERMEDIATES FOR THEIR PREPARATION Aktiebolaget Hässle (SE) 1981-04-29 EP disclosed
US-4255431-A Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion AKTIEBOLAGET HASSLE (SE) 1981-03-10 US disclosed
EP-0005129-A1 Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation Aktiebolaget Hässle (SE) 1979-10-31 EP disclosed